Novartis Reports New Data of Kesimpta (ofatumumab) in ALITHIOS Study for Multiple Sclerosis
Shots: The PALOMA-3 Trial involves assessing of Ibrance (palbociclib) + fulvestrant vs PBO + fulvestrant in women having HR+, HER2- metastatic breast cancer for 2L PALOMA-3 Trial results: mOS (34.9 vs 28.0 mos); mPFS (11.2 vs 4.6 mos); median CT (17.6 vs 8.8 mos.) Ibrance PO is CDKs 4 and 6 inhibitor indicated for HR+, […]Read More
